Inhibitors of the anti-apoptotic Bcl-2 proteins: A patent review

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 1, 2012, Pages 37-55

  Bajwa, Naval ^a   Liao, Chenzhong ^a   Nikolovska Coleska, Zaneta ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

apoptosis; BH3 mimetics; cancer; inhibitors of anti apoptotic Bcl 2 proteins; proteinprotein interactions

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; APOGOSSYPOL; APOGOSSYPOLONE; ASPARAGINASE; BENDAMUSTINE; CAMPTOTHECIN; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; GOSSYPOL; GOSSYPOLIC ACID; GOSSYPOLONIC ACID; ISOSORBIDE; ISOXAZOLIDINE DERIVATIVE; LENALIDOMIDE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PROTEIN BCL 2; PROTEIN BCL 2 INHIBITOR; PROTEIN BCL XL; PROTEIN INHIBITOR; RITUXIMAB; TOPOTECAN; TW 37; UNCLASSIFIED DRUG; UREA DERIVATIVE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ALPHA HELIX; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; GENE EXPRESSION REGULATION; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; KAPOSI SARCOMA; LUNG SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECURRENT CANCER; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PEPTIDOMIMETICS; PEPTIDYLPROLYL ISOMERASE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84855480722     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.644274     Document Type: Review

References (132)

1. Toogood PL. Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem 2002;45:1543-58 (Pubitemid 34293520)
2. Ideker T, Sharan R. Protein networks in disease. Genome Res 2008;22:644-52 (Pubitemid 351482789)
3. Cummings CG, Hamilton AD. Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics. Curr Opin Chem Biol 2010;14:341-6
4. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004;3:301-17 (Pubitemid 38499758)
5. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19 (Pubitemid 38167313)
6. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37 (Pubitemid 46328466)
7. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7:989-1000
8. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009;16:360-7
9. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59
10. Petros AM, Nettesheim DG, Wang Y, et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 2000;9:2528-34 (Pubitemid 32105735)
11. Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183-92 (Pubitemid 41043974)
12. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403 (Pubitemid 40193310)
13. O'Brien SM, Cunningham CC, Golenkov AK, et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:7697-702 (Pubitemid 46291834)
14. Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004;305:1466-70 (Pubitemid 39167667)
15. Wang JL, Zhang ZJ, Choksi S, et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 2000;60:1498-502 (Pubitemid 30183413)
16. Stewart ML, Fire E, Keating AE, Walensky LD. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 2010;6:595-601
17. Walensky LD, Pitter K, Morash J, et al. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 2006;24:199-210 (Pubitemid 44557124)
18. Kutzki O, Park HS, Ernst JT, et al. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc 2002;124:11838-9
19. Davis JM, Truong A, Hamilton AD. Synthesis of a 2,3';6',3''-terpyridine scaffold as an alpha-helix mimetic. Org Lett 2005;7:5405-8 (Pubitemid 41775143)
20. Yin H, Hamilton AD. Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein. Bioorg Med Chem Lett 2004;14:1375-9 (Pubitemid 38299412)
21. Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001;3:173-82 (Pubitemid 32118371)
22. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81 (Pubitemid 40825512)
23. Petros AM, Huth JR, Oost T, et al. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett 2010;20:6587-91
24. Petros AM, Dinges J, Augeri DJ, et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 2006;49:656-63 (Pubitemid 43157495)
25. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000;97:7124-9 (Pubitemid 30431428)
26. Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001;44:4313-24 (Pubitemid 33131658)
27. Bruncko M, Oost TK, Belli BA, et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem 2007;50:641-62 (Pubitemid 46332978)
28. Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006;49:6139-42 (Pubitemid 44595187)
29. Wei J, Kitada S, Stebbins JL, et al. Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2010;53:8000-11
30. Tzung SP, Kim KM, Basanez G, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001;3:183-91 (Pubitemid 32118372)
31. Friedhelm Herrmann. Substance for use against tumor growth and viral infections. WO9704006; 1997
32. Washington University. Cell death agonist. WO9916787; 1999
33. Walter and Eliza Hall Institute of Medical Research. Peptides and their therapeutic uses thereof. WO2004058804A1; 2004
34. Walter and Eliza Hall Institute of Medical Research. Conjugates and therapeutic uses thereof. WO2006000034A1; 2006
35. Dana-Farber Cancer Institute. Stabilized alpha helical peptides and uses thereof. WO2005044839; 2005. US7723469; 2010
36. Coutinho EM, Athayde C, Atta G, et al. Gossypol blood levels and inhibition of spermatogenesis in men taking gossypol as a contraceptive. A multicenter, international, dose-finding study. Contraception 2000;61:61-7 (Pubitemid 30169306)
37. University of Michigan. Small molecule antagonists of Bcl-2 family proteins. WO2002097053A2; 2002. US7432304; 2008
38. University of Michigan. Small molecule antagonists of Bcl-2 family proteins. WO2005069771A2; 2005
39. University of Michigan. Gossypol co-crystals and the use thereof. WO2005094804A1; 2005. US7342046; 2008. US7432300; 2008
40. Kitada S, Leone M, Sareth S, et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46:4259-64 (Pubitemid 37153007)
41. Xu L, Yang D, Wang S, et al. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 2005;4:197-205 (Pubitemid 40340199)
42. Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003;66:93-103 (Pubitemid 36724903)
43. Oliver CL, Miranda MB, Shangary S, et al. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther 2005;4:23-31 (Pubitemid 40268063)
44. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005;4:13-21 (Pubitemid 40268062)
45. Atmaca H, Gorumlu G, Karaca B, et al. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. Eur Cytokine Netw 2009;20:121-30
46. Meng Y, Tang W, Dai Y, et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008;7:2192-202
47. Wolter KG, Wang SJ, Henson BS, et al. (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 2006;8:163-72 (Pubitemid 43671231)
48. Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004;10:7757-63 (Pubitemid 39557541)
49. Bauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther 2005;4:1096-104 (Pubitemid 41079103)
50. Zaidi R, Hadi SM. Complexes involving gossypol, DNA and Cu(II). Biochem Int 1992;28:1135-43
51. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008;112:1971-80
52. Pang X, Wu Y, Lu B, et al. (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther 2011;10:795-805
53. Lian J, Karnak D, Xu L. The Bcl-2-Beclin 1 interaction in (-)-gossypolinduced autophagy versus apoptosis in prostate cancer cells. Autophagy 2010;6:1201-3
54. Ascenta Therapeutics, Inc. Pulsatile dosing of gossypol for treatment of disease. WO2008150506A1; 2008
55. Ascenta Therapeutics, Inc. Process for preparing R-gossypol L-phenyl alaninol dienamine. WO2009045410A1; 2009
56. Heist RS, Fain J, Chinnasami B, et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 2010;5:1637-43
57. Liu G, Kelly WK, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009;15:3172-6
58. University of Michigan. Apogossypolone and the uses thereof. WO2006050447A2; 2006
59. Sun Y, Wu J, Aboukameel A, et al. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol Ther 2008;7:1418-26
60. Hu ZY, Zhu XF, Zhong ZD, et al. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer 2008;123:2418-29
61. Mi JX, Wang GF, Wang HB, et al. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma. Acta Pharmacol Sin 2008;29:1467-77
62. Banerjee S, Choi M, Aboukameel A, et al. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. Pancreas 2010;39:323-31
63. Kitada S, Kress CL, Krajewska M, et al. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 2008;111:3211-19
64. Coward L, Gorman G, Noker P, et al. Quantitative determination of apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/ MS. J Pharm Biomed Anal 2006;42:581-6 (Pubitemid 44636096)
65. Burnham Institute for Medical Research. Naphthale-based inhibitors of anti-apoptotic proteins. WO2009052443A1; 2009. US8039668; 2011
66. Burnham Institute for Medical Research. Naphthale-based inhibitors ofanti-apoptotic proteins. WO2010120943A1; 2010
67. Wei J, Kitada S, Rega MF, et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2009;8:904-13
68. Wei J, Kitada S, Rega MF, et al. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2009;52:4511-23
69. Wei J, Stebbins JL, Kitada S, et al. BI- 97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia- 2 (Bcl-2) family proteins. J Med Chem 2010;53:4166-76
70. Dash R, Azab B, Quinn BA, et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24- mediated toxicity. Proc Natl Acad Sci USA 2011;108:8785-90
71. Azab B, Dash R, Das SK, et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. J Cell Physiol 2011;DOI 10.1002/jcp.22947.
72. University of Michigan. Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof. WO2006023778A2; 2006
73. Mohammad RM, Goustin AS, Aboukameel A, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007;13:2226-35 (Pubitemid 46649892)
74. Zeitlin BD, Joo E, Dong Z, et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006;66:8698-706 (Pubitemid 44449186)
75. Ashimori N, Zeitlin BD, Zhang Z, et al. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther 2009;8:893-903
76. Verhaegen M, Bauer JA, Martin de la Vega C, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006;66:11348-59 (Pubitemid 46009966)
77. Wang Z, Song W, Aboukameel A, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 2008;123:958-66 (Pubitemid 352032427)
78. Mohammad RM, Goustin AS, Aboukameel A, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007;13:2226-35
79. Gemin X Biotechnologies, Inc. Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases. WO2004106328A1; 2004
80. Gemin X Biotechnologies, Inc. Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases. WO2005117908A2; 2005. US7425553; 2008
81. Gemin X Biotechnologies, Inc. Dipyrrole compounds, compositions, and methods for treating cancer or viral diseases. WO2006069441A1; 2006
82. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15- 070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007;104:19512-17
83. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006;13:1419-21 (Pubitemid 44057478)
84. Perez-Galan P, Roue G, Villamor N, et al. The BH3-mimetic GX15- 070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007;109:4441-9 (Pubitemid 46743414)
85. Li J, Viallet J, Haura EB. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol 2008;61:525-34 (Pubitemid 350275989)
86. Trudel S, Li ZH, Rauw J, et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007;109:5430-8 (Pubitemid 46890566)
87. Mott JL, Bronk SF, Mesa RA, et al. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther 2008;7:2339-47
88. Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 2009;15:150-9
89. Witters LM, Witkoski A, Planas-Silva MD, et al. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep 2007;17:465-9
90. Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010;120:1310-23
91. Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008;68:3413-20
92. Schimmer AD, O'Brien S, Kantarjian H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:8295-301
93. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299-305
94. Hwang JJ, Kuruvilla J, Mendelson D, et al. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010;16:4038-45
95. Paik PK, Rudin CM, Brown A, et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 2010;66:1079-85
96. Abbott Laboratories. Apoptosis promoters. US20070072860; 2007. US7642260; 2010. US7973161; 2011
97. Abbott Laboratories. N-acylsulfonamide apoptosis promoters. WO2002024636; 2002. WO2005049593; 2005. WO2005049594; 2005
98. Abbott Laboratories. Apoptosis promoters. US7767684; 2010. US7906505; 2011
99. Abbott Laboratories. Apoptosis promoters. WO2006127364A1; 2006. Macrocyclic Inhibitors of Bcl proteins. US7777076; 2010
100. Abbott Laboratories. N-Sulfonyl carboximidamide apoptosis promoters. WO2005117543A2; 2005. US7585858; 2009
101. Del Gaizo Moore V, Schlis KD, Sallan SE, et al. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008;111:2300-9 (Pubitemid 351451437)
102. Buron N, Porceddu M, Brabant M, et al. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS ONE 2010;5:e9924
103. Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007;21:1549-60 (Pubitemid 46965297)
104. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/ Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007;26:2374-80 (Pubitemid 46572819)
105. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-88 (Pubitemid 44693472)
106. Del Gaizo Moore V, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117:112-21 (Pubitemid 46048458)
107. Vogler M, Dinsdale D, Sun XM, et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008;15:820-30 (Pubitemid 351524424)
108. Kang MH, Kang YH, Szymanska B, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007;110:2057-66 (Pubitemid 47443923)
109. High LM, Szymanska B, Wilczynska-Kalak U, et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 2010;77:483-94
110. Abbott Laboratories. A process for the preparation of the apoptosis promoter ABT-263. WO2009155386A1; 2009
111. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8
112. Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008;14:3268-77
113. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99 (Pubitemid 44711953)
114. Chen S, Dai Y, Harada H, et al. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-91 (Pubitemid 46192219)
115. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011;29:909-16
116. Abbott Laboratories. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. WO2010083442A1; 2010
117. Abbott Laboratories. Bcl-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases. WO2010065865A2; 2010
118. Czabotar PE, Lee EF, van Delft MF, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 2007;104:6217-22 (Pubitemid 47186075)
119. Abbott Laboratories. 7-Nonsubstituted indole Mcl-1 inhibitors. WO2008130970A1; 2008. US7981888B2; 2011
120. Abbott Laboratories. 7-Substituted indole Mcl-1 inhibitors. WO2008131000A2; 2008
121. Abbott Laboratories. Apoptosis promoters. WO2007008627; 2007. US7750004B2; 2010. US7989656B2; 2011
122. Thomas Jefferson University. Synthesis of 4H-chromene derivatives. WO2002060887A2; 2002. US6660871B2; 2003
123. Fred Hutchinson Cancer Research Center. Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins. WO200114365A1; 2001. US7241804B1; 2007
124. Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners. WO2008060569A1; 2008. US7842815; 2010. US7851637; 2010
125. Walter and Eliza Hall Institute of Medical Research. Alpha-helical mimetics. WO2006002474A1; 2006. US7956216B2; 2011
126. Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009;16:1030-9
127. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008;68:2944-51 (Pubitemid 351556295)
128. Tagscherer KE, Fassl A, Campos B, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008;27:6646-56
129. Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 2008;68:7985-94
130. Trudel S, Stewart AK, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007;13:621-9 (Pubitemid 46225369)
131. Deng J, Carlson N, Takeyama K, et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007;12:171-85 (Pubitemid 47199122)
132. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173-86 (Pubitemid 46427871)